Relatlimab and nivolumab in the treatment of melanoma
Details
Publication Year 2022-12-22,Volume 185,Issue #26,Page 4866-4869
Journal Title
Cell
Publication Type
Commentary
Abstract
Combined LAG-3 and PD-1 blockade is an emerging strategy for the treatment of melanoma. Tawbi et al. and Amaria et al. report in The New England Journal of Medicine and Nature respectively on two clinical trials evaluating relatlimab and nivolumab as front-line treatment for metastatic, and resectable, high-risk, node-positive melanoma.
Keywords
Humans; *Nivolumab/therapeutic use; Ipilimumab; *Melanoma/drug therapy/pathology; Antibodies, Monoclonal, Humanized/therapeutic use
Department(s)
Laboratory Research; Medical Oncology
PubMed ID
36563660
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2024-09-26 05:45:18
Last Modified: 2024-09-26 05:48:04

© 2024 The Walter and Eliza Hall Institute of Medical Research. Access to this website is subject to our Privacy Policy and Terms of Use

An error has occurred. This application may no longer respond until reloaded. Reload 🗙